Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
What Could Stall AbbVie Stock's Run?
07.11.2026 10:07
For questions about this article or underlying research, email help@trefis.com.
GLP-1 Drugs Are McDonald’s “Most Powerful Threat” in Decades, Investor Warns
07.11.2026 07:59
Key TakeawaysMcDonald’s shares rose 6% on Nov. 4 after a third-quarter earnings beat, even as U.
Top 3 Biotech Stocks To Watch In November 2026
07.11.2026 05:17
Central banks are signalling that higher interest rates are likely needed to tame stubborn inflation, which keeps borrowing costs elevated and funding more expensive for many risky assets. Yet that pressure has not removed the appeal of high potential growth stories; it has simply raised the bar on quality. This article looks at three biotech stocks that pair this high risk, high reward profile with balance sheets that appear more grounded than many peers. The stocks covered below are just a...
Eli Lilly gets BofA target hike as non-obesity pipeline takes focus
05.11.2026 19:42
Eli Lilly and Co (NYSE:LLY) received a higher price target of $1,557 from Bank of America, which maintained its "buy" rating while highlighting potential upside from drugs beyond obesity. The bank raised its valuation multiple from 25 times to 26 times estimated 2028 underlying earnings per...
4 Healthcare ETFs to Tap Into Eli Lilly's Post-Q3 Earnings Rally
05.11.2026 18:00
Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.
Big pharma-backed T-Therapeutics snags $133m to bring TCEs to clinic
05.11.2026 16:10
T-Therapeutics will now generate proof-of-concept data for its oncology and immunology drugs with “blockbuster” potential.
Eli Lilly and Company’s (LLY) GLP-1 Franchise Faces Growing Price Competition
05.11.2026 15:52
Baron Capital, an investment management company, released its Q3 2026 investor letter for the “Baron Health Care Fund”. The letter can be downloaded here. During the quarter ended September 30, 2026, Baron Health Care Fund® advanced 4.02%, underperforming the Russell 3000 Health Care Index’s 6.19% gain. Since its inception, the Fund’s annualized growth is 10.80%, […]
Prediction: The Weight-Loss Drug Boom Could Be Just the Beginning for Lilly
05.11.2026 14:03
Eli Lilly just crushed earnings and raised guidance, yet the most compelling part of its story has almost nothing to do with what already happened. The real question is whether the weight-loss boom is a peak or a launching pad for something far bigger.
What Changed In Bristol Myers Squibb's Story?
05.11.2026 13:12
For questions about this article or underlying research, email help@trefis.com.
LifeMD expands access to Lilly’s self-pay GLP-1 medicines, enabling option to dispense and ship directly to patients nationwide
05.11.2026 12:30
Eligible patients prescribed Zepbound® or Foundayo® through LifeMD can now receive authentic Lilly medicines at Lilly's self-pay prices through LifeMD's affiliated pharmacyNEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an arrangement with Eli Lilly and Company (Lilly) that enables LifeMD's affiliated pharmacy to directly dispense and ship Lilly's self-pay GLP-1 medicines, including Zepbound® (tirzepatide) and F
Zenith Epigenetics Announces Clinical Trial Collaboration and Supply Agreement with Lilly for Registration Enabling Study of ZEN-3694 and Verzenio(R) (Abemaciclib) in NUT Carcinoma
05.11.2026 12:15
Calgary, Alberta--(Newsfile Corp. - November 5, 2026) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") today announced that the Company has executed a Clinical Trial Collaboration and Supply Agreement ("CTCSA") with Eli Lilly & Company ("Lilly") for the upcoming registration enabling study of ZEN-3694, the Company's clinical oncology candidate, and Lilly's CDK4/6 inhibitor, Verzenio (abemaciclib), for the treatment of NUT carcinoma. Under the terms of the agreement, Zenith will sponsor and.
Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
05.11.2026 12:09
Blue Wave election results could reshape healthcare policy. Click to discover stocks that need to be watched in the Big Pharma and biotech sectors.
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
05.11.2026 11:45
Eli Lilly and Company (NYSE: LLY) will present new clinical and real-world research in people with knee osteoarthritis pain and obesity and those with psoriatic arthritis and obesity at the American College of Rheumatology (ACR) Convergence 2026, taking place Nov. 6-11 in Orlando. Presentations will highlight new findings for retatrutide, an investigational once-weekly GIP, GLP-1, and glucagon triple hormone receptor agonist, with a plenary session detailing improvements in knee pain and physica
What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Nov. 3
05.11.2026 11:05
The fund added $330.3 million in net purchases, lifting all 60 of its positions with no sells.
ETFs Bought $90.0 Million of Lilly (LLY) on Nov. 3
05.11.2026 11:01
39 ETFs bought Lilly shares versus 12 that sold on Tuesday, Nov. 3.
Why Did Pfizer Stop Talking Up This Business?
05.11.2026 10:35
For questions about this article or underlying research, email help@trefis.com.
LifeMD Announces Agreement For Its Pharmacies To Directly Dispense, Ship Eli Lilly's Self-Pay GLP-1 Medicines
05.11.2026 08:36
LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an arrangement with Eli Lilly and Company (Lilly) that enables LifeMD's affiliated pharmacy to directly dispense and ship
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
05.11.2026 07:00
$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M-Ventures and Lilly, joined by all existing major shareholders Proceeds to fund two first-in-class TCR-CD3 bispecific programmes in cancer and autoimmune disease through to clinical proof-of-conceptDr. Kirsty Crame appointed Chief Development Officer to oversee translational and clinical
Eli Lilly (LLY) Wins Ad Changes On Weight Loss Drugs And Recasts Its Pipeline
05.11.2026 06:14
Eli Lilly (NYSE:LLY) has intensified legal and regulatory pressure on providers of compounded Tirzepatide+ weight loss drugs, challenging safety and marketing claims. The drugmaker has secured changes to a competitor's advertising for compounded Tirzepatide+ products after raising concerns about product integrity and patient protection. Management is reshaping Eli Lilly's research pipeline through sizeable acquisitions, program divestments, and discontinuations that tilt investment toward...
Eli Lilly Is Up 10% in a Week. Is a $5.5 Billion Guidance Raise Really That Good?
05.11.2026 03:23
Key TakeawaysEli Lilly stock is up 10% in a week after third-quarter revenue jumped 39% and Lilly raised its 2026 sales forecast to $91-$92 billion. Volume rose 53% while realized prices fell 15%, so the raise rests on demand.